WW International

WW International reduced debt from about $1.6bn to just above $400m, halving interest expense and expects to be free-cash-flow positive this year while reinvesting in growth. Clinical subscribers rose nearly 56% in Q2 and the company projects clinical revenue will reach 25%–30% of total revenue in 2026 as GLP-1 telehealth offerings expand. Management guided 2026 revenue of $620m–$635m and adjusted EBITDA of $105m–$115m, increased marketing to raise GLP-1 awareness and expanded partnerships including Sam's Club and LillyDirect. Adjusted gross margins remain near 73% and the company highlighted app enhancements and behavioral programs to differentiate its services. » More on finance.yahoo.com

WW International shares climbed 3.1% after the close to $17.21, continuing their recovery from the 52-week low despite no new company-specific news. Drivers were strong Q2 results (EPS $1.41 vs. $0.89 consensus), a confirmed full-year revenue guide of $620–635 million, and 32% revenue growth in the clinical subscriptions segment. Additional support came from insider purchases and the disclosure of roughly an 8.4% stake by an activist investor, while thin after-hours volume and the micro-cap structure amplified the price move. » More on de.investing.com

Wolverine World Wide will pay a quarterly cash dividend of $0.10 per common share, payable on August 3, 2026 to shareholders of record on July 1, 2026. The payment matches the prior quarter and implies an annualized dividend of $0.40 per share with a dividend yield of 2.38%. The company has maintained dividend payments for 39 consecutive years; the stock is trading at $17.26 and is rated undervalued by InvestingPro. » More on de.investing.com

WW International announced it will use up to $40 million in cash to prepay and reduce the outstanding principal of its term loan. Of that amount, $25–30 million is expected to be paid via an accelerated payment of the annual cash sweep (due June 24, 2026) and up to $10 million via a voluntary discounted repurchase offer (expected to end April 30, 2026). The company reiterates its subscriber and full-year 2026 guidance and notes it expects to generate cash later in the year after seasonal cash consumption in the first quarter. WW has total debt of $468.62 million and a market capitalization of $92.67 million. » More on de.investing.com

Cedar Grove Capital Management said it heavily reduced and then fully exited its position in WW International after a surprising sequential decline in behavioral subscribers and the March 31 departure of CEO Tara. The firm had initially bought WW post‑bankruptcy, citing debt reduction and strong clinical growth from the Wegovy Pill, but cited risk management and unfavorable market conditions as reasons to redeploy capital. WW shares have fallen sharply year‑to‑date and the company has a market capitalization around $110 million. » More on finance.yahoo.com